Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 17 results.
User Information
Export Records
  1. 1.   New flow cytometric assays for monitoring cell-mediated cytotoxicity
  2. Zaritskaya, L.; Shurin, M. R.; Sayers, T. J.; Malyguine, A. M.
  3. Expert Review of Vaccines. 2010, Jun; 9(6): 601-616.
  1. 2.   Detoxification of Gold Nanorods by Treatment with Polystyrenesulfonate
  2. Leonov, A. P.; Zheng, J. W.; Clogston, J. D.; Stern, S. T.; Patri, A. K.; Wei, A.
  3. Acs Nano. 2008 2(12): 2481-2488.
  1. 3.   The NCI60 human tumour cell line anticancer drug screen
  2. Shoemaker, R. H.
  3. Nature Reviews Cancer. 2006, Oct; 6(10): 813-823.
  1. 4.   Cytotoxicity and apoptosis of benzoquinones: redox cycling, cytochrome c release, and BAD protein expression
  2. Tudor, G.; Gutierrez, P.; Aguilera-Gutierrez, A.; Sausville, E. A.
  3. Biochemical Pharmacology. 2003 65(7): 1061-1075.
  1. 5.   O-6-benzylguanine-mediated enhancement of chemotherapy
  2. Friedman, H. S.; Keir, S.; Pegg, A. E.; Houghton, P. J.; Colvin, O. M.; Moschel, R. C.; Bigner, D. D.; Dolan, M. E.
  3. Molecular Cancer Therapeutics. 2002 1(11): 943-948.
  1. 6.   Human topoisomerase I inhibition: Docking camptothecin and derivatives into a structure-based active site model
  2. Laco, G. S.; Collins, J. R.; Luke, B. T.; Kroth, H.; Sayer, J. M.; Jerina, D. M.; Pommier, Y.
  3. Biochemistry. 2002 41(5): 1428-1435.
  1. 7.   Phase II trial of carmustine plus O-6-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma
  2. Quinn, J. A.; Pluda, J.; Dolan, M. E.; Delaney, S.; Kaplan, R.; Rich, J. N.; Friedman, A. H.; Reardon, D. A.; Sampson, J. H.; Colvin, O. M.; Haglund, M. M.; Pegg, A. E.; Moschel, R. C.; McLendon, R. E.; Provenzale, J. M.; Gururangan, S.; Tourt-Uhlig, S.; Herndon, J. E.; Bigner, D. D.; Friedman, H. S.
  3. Journal of Clinical Oncology. 2002 20(9): 2277-2283.
  1. 8.   Three-color flow cytometric assay for the study of the mechanisms of cell-mediated cytotoxicity
  2. Derby, E.; Reddy, V.; Kopp, W.; Nelson, E.; Baseler, M.; Sayers, T.; Malyguine, A.
  3. Immunology Letters. 2001 78(1): 35-39.
  1. 9.   Hamster and rat fetal cells have low spontaneous mutation frequencies and rates
  2. Donovan, P. J.; Smith, G. T.; Riggs, C. W.
  3. Mutation Research-Fundamental and Molecular Mechanisms of Mutagenesis. 2001 478(1-2): 51-63.
  1. 10.   Unlocking the secrets of cytotoxic granule proteins
  2. Smyth, M. J.; Kelly, J. M.; Sutton, V. R.; Davis, J. E.; Browne, K. A.; Sayers, T. J.; Trapani, J. A.
  3. Journal of Leukocyte Biology. 2001 70(1): 18-29.
  1. 11.   Phase I trial of carmustine plus O-6-benzylguanine for patients with recurrent or progressive malignant glioma
  2. Friedman, H. S.; Pluda, J.; Quinn, J. A.; Ewesuedo, R. B.; Long, L.; Friedman, A. H.; Cokgor, I.; Colvin, O. M.; Haglund, M. M.; Ashley, D. M.; Rich, J. N.; Sampson, J.; Pegg, A. E.; Moschel, R. C.; McLendon, R. E.; Provenzale, J. M.; Stewart, E. S.; Tourt-Uhlig, S.; Garcia-Turner, A. M.; Herndon, J. E.; Bigner, D. D.; Dolan, M. E.
  3. Journal of Clinical Oncology. 2000 18(20): 3522-3528.
  1. 12.   The virus-specific and allospecific cytotoxic T-lymphocyte response to lymphocytic choriomeningitis virus is modified in a subpopulation of CD8(+) T cells coexpressing the inhibitory major histocompatibility complex class I receptor Ly49G2
  2. Peacock, C. D.; Lin, M. Y.; Ortaldo, J. R.; Welsh, R. M.
  3. Journal of Virology. 2000 74(15): 7032-7038.
  1. 13.   A Phase Ii Study of Carboplatin, Cisplatin, Interferon-Alpha, and Tamoxifen For Patients With Metastatic Melanoma
  2. Gause, B. L.; Sharfman, W. H.; Janik, J. E.; Curti, B. D.; Steis, R. G.; Urba, W. J.; Smith, J. W.; Alvord, W. G.; Longo, S. L.
  3. Cancer Investigation. 1998 16(6): 374-380.
  1. 14.   Phase I Trial of O-6-Benzylguanine For Patients Undergoing Surgery For Malignant Glioma
  2. Friedman, H. S.; Kokkinakis, D. M.; Pluda, J.; Friedman, A. H.; Cokgor, I.; Haglund, M. M.; Ashley, D. M.; Rich, J.; Dolan, M. E.; Pegg, A. E.; Moschel, R. C.; McLendon, R. E.; Kerby, T.; Herndon, J. E.; Bigner, D. D.; Schold, S. C.
  3. Journal of Clinical Oncology. 1998 16(11): 3570-3575.
  1. 15.   Developmental Differences Determine Larval Susceptibility to Nitric Oxide-Mediated Killing in a Murine Model of Vaccination Against Schistosoma Mansoni
  2. Ahmed, S. F.; Oswald, I. P.; Caspar, P.; Hieny, S.; Keefer, L.; Sher, A.; James, S. L.
  3. Infection and Immunity. 1997 65(1): 219-226.
  1. 16.   Progesterone Pretreatment Enhances Cellular Sensitivity to Cadmium Despite a Marked Activation of the Metallothionein Gene
  2. Shimada, H.; Hochadel, J. F.; Waalkes, M. P.
  3. Toxicology and Applied Pharmacology. 1997 142(1): 178-185.
  1. 17.   Association of Arsenic-Induced Malignant Transformation With Dna Hypomethylation and Aberrant Gene Expression
  2. Zhao, C. Q.; Young, M. R.; Diwan, B. A.; Coogan, T. P.; Waalkes, M. P.
  3. Proceedings of the National Academy of Sciences of the United States of America. 1997 94(20): 10907-10912.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel